undefined undefined
NaN.000
NaN.00%
作为科技产业皇冠上的明珠,全球创新药市场,美国占55%,中国仅有3%。 但我国却是世界第二大医药消费国,创新能力的孱弱和庞大的需求极不相符。 如今,这个尴尬的局...
今天 07:58
吉利德(GILD.US)、Arcellx在Clinicaltrials.gov网站上注册了Anitocabtagene Autoleucel治疗复发性或难治性多发性骨髓瘤的三期临床试验。
05-16 21:10
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our a...
05-16 01:46
蓝鲸财经 屠俊 CD47一直被业内认为是继PD-1之后免疫治疗领域的又一潜力“吸金”靶点,虽然包括吉利德科学、艾伯维、罗氏、辉瑞在内的多家跨国药企纷纷下注,但至...
05-15 10:56
为缩减成本,寻求新的市场增长点,精简产品管线也是跨国药企的一项重要手段。 近日,百时美施贵宝(BMS)在其第一季度报告中表示,计划在2025年底前通过大...
05-15 05:00
Xilio Therapeutics press release (NASDAQ:XLO): Q1 GAAP EPS of -$0.62. Cash and cash equivalents were $34.0 million as of March 31, 2024, compared to $44.7 million as of December 31, 2023. More on Xili...
05-14 21:22
Merck (NYSE:MRK) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. KeyVibe-010, a randomized Phase 3 trial, was testing the investigational cofor...
05-13 19:58
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported ...
05-13 19:00
①宜明昂科坚定推进其CD47管线临床,公司All in CD47的底气和前景到底如何? ②田文志透露,宜明昂科正在跟海外药企积极沟通管线产品的海外授权合作,希望...
05-12 12:14